Step 1 topics → Endocrine → Acromegaly / Gigantism (GH-Secreting Adenoma)

Acromegaly / Gigantism (GH-Secreting Adenoma)

USMLE Step 1 trap: Uses random GH rather than IGF-1 as the screening test for acromegaly. IGF-1 is the best screening test for acromegaly because it reflects integrated GH secretion; random GH is unreliable due to pulsatile secretion.

Acromegaly and gigantism both result from a GH-secreting pituitary adenoma, and USMLE Step 1 tests this from multiple angles. Students consistently order random serum GH for screening — the wrong test, because GH is pulsatile — when the correct first test is IGF-1. They also misattribute the tissue enlargement to direct GH action when it's actually mediated through hepatic IGF-1. Excess GH before epiphyseal closure causes gigantism; after closure it causes acromegaly (coarse features, spade hands, carpal tunnel, skin tags). Cardiovascular disease, not colon cancer, is the leading cause of death.

The exam will test you on multiple levels: pure recall (what are the features?), application (what test do you order next?), and mechanism (why does tissue enlargement happen?). A common error is jumping straight to random serum GH for diagnosis — the exam knows this is a trap because GH secretion is pulsatile and a single level is meaningless. The correct screening test is IGF-1, and the confirmatory test is an oral glucose tolerance test (OGTT) checking whether GH suppresses appropriately. Students who miss this get burned on 'what is the next step' questions.

Another high-yield trap: most of GH's growth-promoting effects are not direct — they're mediated through IGF-1 (somatomedin C) produced by the liver. GH has direct metabolic effects (anti-insulin, lipolysis), but the tissue growth that defines acromegaly is largely an IGF-1 story. USMLE Step 1 exploits this in mechanism questions. Similarly, students often overcorrect toward colon cancer as the cause of death (it's a real risk, just not the leading one) — cardiovascular disease from cardiomegaly and cardiomyopathy kills these patients most often.

From real student decks
81%have cards covering this topic
70%have mature cards
1.0median lapses in 14 days

Common misconceptions

Common mistake
Wrong: A random serum GH level is the best screening test for acromegaly.
Right: IGF-1 is the best screening test for acromegaly because it reflects integrated GH secretion; random GH is unreliable due to pulsatile secretion.
Random serum GH is unreliable because GH is secreted in pulses — a single draw could be at a trough and be falsely normal even in active disease. IGF-1 (somatomedin C) reflects the cumulative effect of GH over hours and has a much longer half-life, making it the right screening test. Think of IGF-1 as a 'running average' of GH activity, analogous to how HbA1c reflects average glucose.
Common mistake
Wrong: An elevated IGF-1 alone confirms acromegaly without further testing.
Right: Confirmation requires an oral glucose tolerance test (OGTT); failure of GH to suppress below 1 ng/mL after glucose load confirms acromegaly.
An elevated IGF-1 raises suspicion but isn't sufficient alone — IGF-1 can be elevated in other states (puberty, pregnancy). The confirmatory step is the OGTT: in normal physiology, a glucose load suppresses GH; in acromegaly, the tumor secretes GH autonomously and GH fails to suppress below 1 ng/mL. This autonomy is the key concept — the tumor doesn't respond to normal feedback signals.
Common mistake
Wrong: The leading cause of death in acromegaly is colon cancer.
Right: The leading cause of death in acromegaly is cardiovascular disease (cardiomegaly, cardiomyopathy, hypertension), not colon cancer, although colon cancer risk is also increased.
Colon cancer risk is genuinely increased in acromegaly (partly through IGF-1's mitogenic effects), so this misconception is understandable — but the leading cause of death is cardiovascular disease. GH excess causes cardiomegaly, cardiomyopathy, and hypertension, which together kill these patients most often. Know both the increased colon cancer risk AND the cardiovascular mortality hierarchy for the exam.
Common mistake
Wrong: GH directly causes the tissue growth effects in acromegaly.
Right: Most growth-promoting effects of GH are mediated indirectly through IGF-1 (somatomedin C) produced primarily by the liver.
GH has two categories of effects: direct metabolic effects (raises blood glucose, promotes lipolysis — think counter-insulin) and indirect growth-promoting effects mediated through IGF-1. After GH binds its receptor in the liver, hepatocytes secrete IGF-1, which then acts on bones, cartilage, and soft tissues to drive the enlargement seen in acromegaly. This is why pegvisomant (a GH receptor antagonist) works — blocking GH signaling cuts off IGF-1 production and halts growth effects.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Recognize the classic adult presentation of acromegaly: coarse facial features, frontal bossing, macroglossia, enlarged spade-shaped hands, skin tags, and carpal tunnel syndrome — and distinguish it from gigantism based on whether epiphyseal plates are open or closed.
  2. Know the correct diagnostic sequence: IGF-1 is the best initial screening test (reflects integrated GH secretion); if elevated, confirm with an OGTT — failure of GH to suppress below 1 ng/mL after glucose load confirms the diagnosis.
  3. Understand surgical vs. pharmacologic management: transsphenoidal resection is first-line; somatostatin analogs (octreotide) reduce GH secretion; pegvisomant is a GH receptor antagonist used when other treatments fail.
  4. Identify the leading cause of death in acromegaly as cardiovascular disease (cardiomegaly, cardiomyopathy, hypertension) — not colon cancer, which is an associated risk but not the top killer.
  5. Explain the GH-IGF-1 axis mechanistically: GH stimulates hepatic IGF-1 production, and IGF-1 is the primary mediator of the tissue and bony growth effects seen in acromegaly — GH's direct effects are predominantly metabolic.

Can you avoid these mistakes?

A 45-year-old man reports that his ring size has increased and his shoe size has gone up two sizes over the past 5 years. He also notes bilateral hand numbness and was recently told his blood pressure is elevated. You suspect acromegaly. What is the best initial test to order, and what result would prompt you to do a confirmatory test?
You order a confirmatory test for acromegaly: an oral glucose tolerance test. Explain the physiologic rationale — what should happen to GH in a normal person after glucose ingestion, and what pattern confirms acromegaly?
A patient with known acromegaly asks about long-term risks. You counsel her that her leading risk of death is from which organ system, and what is the second most concerning malignancy risk she faces?
A pharmacology question asks about pegvisomant vs. octreotide for treating acromegaly. Explain the mechanism of each drug and identify one scenario where pegvisomant would be preferred over octreotide.

Related topics

Hormone Signaling (Peptide vs Steroid) Hypothalamic-Pituitary-Adrenal (HPA) Axis Hypothalamic-Pituitary-Thyroid (HPT) Axis Hypothalamic-Pituitary-Gonadal (HPG) Axis

See how your Anki deck covers this topic.

Upload your deck for a free audit →